Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

Further, the study showed that nirsevimab’s effect was less pronounced in older children (between six and 23 months), ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Nirsevimab, a long-acting monoclonal antibody, was introduced last season (2023–2024) in some countries with the aim of ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the ...